Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Abiraterone for Treatment of Metastatic Castration-resistant Prostate Cancer: a Systematic Review and Meta-analysis

  • Zhou, Zhi-Rui (Department of Radiation Oncology, Tumor Hospital of Jilin Province) ;
  • Liu, Shi-Xin (Department of Radiation Oncology, Tumor Hospital of Jilin Province) ;
  • Zhang, Tian-Song (Internal Medicine of Traditional Chinese Medicine Department, Jing'an District Central Hospital of Shanghai) ;
  • Xia, Jun (Cochrane Schizophrenia Group, the University of Nottingham) ;
  • Li, Bo (Department of Digestive System, Xiyuan Hospital, China Academy of Traditional Chinese Medicine)
  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Introduction: Although most prostate cancers initially respond to castration with luteinizing hormonereleasing analogues or bilateral orchiectomy, progression eventually occurs. Based on the exciting results of several randomized controlled trials (RCTs), it seems that patients with metastatic castration-resistant prostate cancer (mCRPC) might benefit more from treatment withabiraterone. Therefore we conducted a systematic review to evaluate the efficacy and toxicity of abiraterone in the treatment of mCRPC. Methods: Literature was searched from Embase, PubMed, Web of Science, and Cochrane Library up to July, 2013. Quality of the study was evaluated according to the Cochrane's risk of bias of randomized controlled trial (RCT) tool, then the Grading of Recommendations Assessment, Development and Evaluation (GRADE) System was used to rate the level of evidence. Stata 12.0 was used for statistical analysis. Summary data from RCTs comparing abiraterone plus prednisone versus placebo plus prednisone for mCRPC were meta-analyzed. Pooled hazard ratios (HRs) for overall survival (OS), radiographic progression-free survival (RPFS) and time to PSA progression (TTPP); Pooled risk ratios (RR) for PSA response rate, objective response rate and adverse event were calculated. Results: Ten trials were included in the systematic review; Data of 2,283 patients (1,343 abiraterone; 940 placebo) from two phase 3 trials: COU-AA-301 and COU-AA-302 were meta-analyzed. Compared with placebo, abiraterone significantly prolonged OS (HR, 0.74; 95% confidence interval [CI], 0.66 to 0.84), RPFS (HR, 0.59; 95% CI, 0.48 to 0.74) and time to PSA progression (HR, 0.55; 95% CI, 0.43 to 0.70); it also significantly increased PSA response rate (RR, 3.63; 95% CI, 1.72 to 7.65) and objective response rate (RR, 3.05; 95% CI, 1.51 to 6.15). This meta-analysis suggested that the adverse events caused by abiraterone are acceptable and can be controlled. Conclutios: Abiraterone significantly prolonged OS, RPFS and time to progression patients with mCRPC, regardless of prior chemotherapy or whether chemotherapy-na$\ddot{i}$ve, and no unexpected toxicity was evident. Abiraterone can serve as a new standard therapy for mCRPC.

Keywords

References

  1. Attard G, Reid AHM, Yap TA, et al (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol, 26, 4563-71. https://doi.org/10.1200/JCO.2007.15.9749
  2. Attard G, Reid AH, A'Hern R, et al (2009). Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol, 27, 3742-8. https://doi.org/10.1200/JCO.2008.20.0642
  3. Balshem H, Helfand M, Schunemann HJ, et al (2011). GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol, 64, 401-6. https://doi.org/10.1016/j.jclinepi.2010.07.015
  4. Beltran H, Beer TM, Carducci MA, et al (2011). New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol, 60, 279-90. https://doi.org/10.1016/j.eururo.2011.04.038
  5. Cersosimo RJ (2012). New agents for the management of castration-resistant prostate cancer. Ann Pharmacother, 46, 1518-28. https://doi.org/10.1345/aph.1R169
  6. Crawford ED, Eisenberger MA, McLeod DG, et al (1989). A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med, 321, 419-24. https://doi.org/10.1056/NEJM198908173210702
  7. Danila DC, Morris MJ, de Bono JS, et al (2010). Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol, 28, 1496-501. https://doi.org/10.1200/JCO.2009.25.9259
  8. de Bono JS, Logothetis CJ, Molina A, et al (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med, 364, 1995-2005. https://doi.org/10.1056/NEJMoa1014618
  9. Di Lorenzo G, Ferro M, Buonerba C (2012). Sipuleucel-T (Provenge (R)) for castration-resistant prostate cancer. BJU Int, 110, E99-104. https://doi.org/10.1111/j.1464-410X.2011.10790.x
  10. Ding H, Yang L, Du W, et al (2013). Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis. Asian Pac J Cancer Prev, 14, 3337-43. https://doi.org/10.7314/APJCP.2013.14.5.3337
  11. Fizazi K, Scher HI, Molina A, et al (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 13, 983-92. https://doi.org/10.1016/S1470-2045(12)70379-0
  12. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A (2011). GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol, 64, 380-2. https://doi.org/10.1016/j.jclinepi.2010.09.011
  13. Higgins JPT, Green S (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
  14. Kang DI, Chung JI, Ha HK, et al (2013). Korean prostate cancer patients have worse disease characteristics than their American counterparts. Asian Pac J Cancer Prev, 14, 6913-7. https://doi.org/10.7314/APJCP.2013.14.11.6913
  15. Logothetis CJ, Basch E, Molina A, et al (2012). Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol, 13, 1210-7. https://doi.org/10.1016/S1470-2045(12)70473-4
  16. Moore MA, Ariyaratne Y, Badar F, et al (2010). Cancer epidemiology in South Asia - past, present and future. Asian Pac J Cancer Prev, 11 Suppl 2, 49-66.
  17. Nandha R (2012). Abiraterone acetate: a novel drug for castration-resistant prostate carcinoma. J Postgrad Med, 58, 203-6. https://doi.org/10.4103/0022-3859.101400
  18. Ostale S, Ruiz P (2012). Cost-efficacy analysis of licensed drugs for the treatment of metastatic castrate resistant prostate cancer post docetaxel based on hospital drug evaluation methodology in Spain. Value Health, 15, A417.
  19. Persson U, Nilsson S, Hjortsberg C, Prutz C (2012). Economic evaluation of abiraterone acetate as treatment for metastatic castration resistant prostate cancer after failure of docetaxel in Sweden. Value Health, 15, A219.
  20. Petrylak DP, Tangen CM, Hussain MH, et al (2004). Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med, 351, 1513-20. https://doi.org/10.1056/NEJMoa041318
  21. Reid AHM, Attard G, Danila DC, et al (2010). Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol, 28, 1489-95. https://doi.org/10.1200/JCO.2009.24.6819
  22. Ryan CJ, Smith MR, Fong L, et al (2010). Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol, 28, 1481-8. https://doi.org/10.1200/JCO.2009.24.1281
  23. Ryan CJ, Shah S, Efstathiou E, et al (2011). Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res, 17, 4854-61. https://doi.org/10.1158/1078-0432.CCR-11-0815
  24. Ryan CJ, Smith MR, de Bono JS, et al (2012). Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, 368, 138-48.
  25. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29. https://doi.org/10.3322/caac.20138
  26. Yang LPH (2011). Abiraterone acetate: In metastatic castrationresistant prostate cancer. Drugs, 71, 2067-77. https://doi.org/10.2165/11208080-000000000-00000
  27. Zhou ZR, Zhu XD, Xia J, et al (2013). Short-term versus longterm hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol, 139, 783-96. https://doi.org/10.1007/s00432-013-1383-7

Cited by

  1. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer vol.10, pp.7, 2015, https://doi.org/10.1371/journal.pone.0133803
  2. Is it Time to Change the Control Placebo Arms in Phase III Trials of Metastatic Castration Resistant Prostate Cancer? vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6167
  3. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study vol.23, pp.5, 2016, https://doi.org/10.1111/iju.13051
  4. Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival vol.7, pp.1663-9812, 2016, https://doi.org/10.3389/fphar.2016.00123
  5. CYP17 inhibitors in prostate cancer: latest evidence and clinical potential vol.8, pp.4, 2016, https://doi.org/10.1177/1758834016642370
  6. Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel vol.28, pp.9, 2017, https://doi.org/10.1097/CAD.0000000000000549
  7. New horizons in the management of castrate-resistant prostate cancer pp.2051-4166, 2017, https://doi.org/10.1177/2051415817731397